BioAge Labs (BIOA) Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BIOA Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
BioAge Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.61 |
| 52 Week High | US$24.00 |
| 52 Week Low | US$3.79 |
| Beta | 0 |
| 1 Month Change | -2.58% |
| 3 Month Change | -22.20% |
| 1 Year Change | 309.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.28% |
Recent News & Updates
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
A week ago, BioAge Labs, Inc. ( NASDAQ:BIOA ) came out with a strong set of first-quarter numbers that could...BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year
Summary BioAge Labs is rated Buy, leveraging strong early data for BGE-102, a novel oral NLRP3 inhibitor targeting cardiovascular and ophthalmology markets. BGE-102 achieved 86% hsCRP reduction and favorable safety in Phase 1, positioning BIOA for a pivotal Phase 2a trial in 2H 2026. BIOA holds ~$285M in cash post-raise, funding operations through 2029 and supporting multiple clinical milestones, including new obesity and ophthalmology candidates. Strategic partnerships with Eli Lilly and Novartis, plus a differentiated mechanism, offer upside, but investors should weigh high clinical and competitive risks. Read the full article on Seeking AlphaRecent updates
Shareholder Returns
| BIOA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.9% | 5.3% | 1.1% |
| 1Y | 309.1% | 44.3% | 28.7% |
Return vs Industry: BIOA exceeded the US Pharmaceuticals industry which returned 44.3% over the past year.
Return vs Market: BIOA exceeded the US Market which returned 28.7% over the past year.
Price Volatility
| BIOA volatility | |
|---|---|
| BIOA Average Weekly Movement | 11.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIOA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BIOA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 61 | Kristen Fortney | bioagelabs.com |
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.
BioAge Labs, Inc. Fundamentals Summary
| BIOA fundamental statistics | |
|---|---|
| Market cap | US$738.36m |
| Earnings (TTM) | -US$89.93m |
| Revenue (TTM) | US$10.32m |
Is BIOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOA income statement (TTM) | |
|---|---|
| Revenue | US$10.32m |
| Cost of Revenue | US$83.27m |
| Gross Profit | -US$72.95m |
| Other Expenses | US$16.98m |
| Earnings | -US$89.93m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.02 |
| Gross Margin | -707.16% |
| Net Profit Margin | -871.75% |
| Debt/Equity Ratio | 0.3% |
How did BIOA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/24 05:46 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioAge Labs, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Samantha Lynn Semenkow | Citigroup Inc |
| Samantha Lynn Semenkow | Citigroup Inc |